Lupin has enclosed a Press Release regarding the appointment of Abdelaziz Toumi as the Chief Executive Officer of the Company’s newly formed subsidiary, Lupin Manufacturing Solutions (‘LMS’). LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations business. The above may be considered as disclosure pursuant to Regulation 30 of the Listing Regulations. The above is for information and dissemination.
The above information is a part of company’s filings submitted to BSE.
